{"id":137018,"date":"2022-11-22T03:40:20","date_gmt":"2022-11-22T08:40:20","guid":{"rendered":"https:\/\/44.250.171.167\/?p=137018"},"modified":"2022-11-22T03:40:21","modified_gmt":"2022-11-22T08:40:21","slug":"orchid-pharma-ltd-q2-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-q2-fy23-earnings-conference-call-insights\/","title":{"rendered":"Orchid Pharma Ltd Q2 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><strong>Key highlights from Orchid Pharma Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/ORCHPHARMA\/\">ORCHPHARMA<\/a>) Q2 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>[00:05:20] Rupesh Jain from Intelsense Capital asked about capacity utilization in 1H23. Mridul Dhanuka Director replied that on the sterile plant the utilization roughly is 90%. And the oral plant it\u2019s about 70%.<\/li>\n<\/ul>\n<ul>\n<li>[00:08:27] Rupesh Jain from Intelsense Capital enquired that in FY23, on current capacity, what\u2019s the peak revenue the company can do. Mridul Dhanuka Director said that it depends on the product mix. The company added that whatever capacity it\u2019s adding will help in continuing the growth momentum and by changing the product mix, ORCHPHARMA can manage that.<\/li>\n<\/ul>\n<ul>\n<li>[00:09:47] Rupesh Jain from Intelsense Capital asked about the proportion of business contribution from India. Sunil Gupta CFO answered that it was around 15%.<\/li>\n<\/ul>\n<ul>\n<li>[00:11:33] Rupesh Jain from Intelsense Capital enquired how the company is looking at India business geographically. Mridul Dhanuka Director said the company is only a B2B business currently as it sells only to the company that make injection or tablet final products. So geography doesn\u2019t matter.<\/li>\n<\/ul>\n<ul>\n<li>[00:16:51] Himanshu Upadhyay of O3 Capital asked about the order book comparison YoverY. Mridul Dhanuka Director said that it would be in line with the growth of company\u2019s expectation. However, exact numbers cannot be given.<\/li>\n<\/ul>\n<ul>\n<li>[00:21:57] Nikhil Upadhyay with SiMPL investment asked about the reason for significant deterioration in P&amp;L in 2Q23. Mridul Dhanuka Director said it\u2019s due to the combination of regulated market vs. emerging market, increase in RM prices and product mix.<\/li>\n<\/ul>\n<ul>\n<li>[00:26:23] Viraj Parekh of Carnelian Asset Management enquired about Europe relationships being restored but the demand being still subdued. Mridul Dhanuka Director said that it should be in the similar range. Around 40% comes from Europe. It\u2019s grown in absolute value but in terms of percentage contribution it might have fallen by 1-2% vs. last year.<\/li>\n<\/ul>\n<ul>\n<li>[00:30:34] Viraj Parekh of Carnelian Asset Management asked about the timeline in terms of promoter stake that needs to be reduced. Mridul Dhanuka Director answered that the timeline is at March 31, 2023, as per SEBI guidelines.<\/li>\n<\/ul>\n<ul>\n<li>[00:30:41] Viraj Parekh of Carnelian Asset Management also asked about the regulated unregulated mix for 2Q23 or 1H23. Mridul Dhanuka Director said that it should be close to the overall number which is one to two third.<\/li>\n<\/ul>\n<ul>\n<li>[00:31:47] Rupesh Tatia with IntelSense Capital asked about the 2H product mix generally. Mridul Dhanuka Director said that H2 numbers are generally higher gross margin kind of half. But the current war is definitely affecting the Europe market.<\/li>\n<\/ul>\n<ul>\n<li>[00:34:30] Rupesh Tatia with IntelSense Capital enquired about royalty for China market, when it\u2019s expected. Mridul Dhanuka Director clarified that whenever the sales start, the royalty would start. Also, there are no milestone payments.<\/li>\n<\/ul>\n<ul>\n<li>[00:40:54] Tarang Agrawal with Old Bridge asked about the company\u2019s dependence on Penicillin G and 7-ACA currently in terms of the quantum. Mridul Dhanuka Director said that the company doesn\u2019t use any Pen G directly.<\/li>\n<\/ul>\n<ul>\n<li>[00:41:07] Tarang Agrawal with Old Bridge also asked about the pricing for Penicillin G and 7-ACA and the drivers of it. Mridul Dhanuka Director answered that current Pen G price is somewhere around $20, which used to be $9 a few years before. 7-ACA current price continue to stay around $60-65 and have not be elevated much in the past and is not expected to change much going forward.<\/li>\n<\/ul>\n<ul>\n<li>[00:46:56] Viraj Parekh of Carnelian Asset Management asked about the capex incurred for capacity expansion in oral and sterile. Mridul Dhanuka Director said that on the sterile plant the capex is INR50 crore, and on oral, expansion would be around INR20-30 crore. For 7-ACA, closer to INR400-500 crore.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Orchid Pharma Ltd (ORCHPHARMA) Q2 FY23 Earnings Concall Q&amp;A Highlights: [00:05:20] Rupesh Jain from Intelsense Capital asked about capacity utilization in 1H23. Mridul Dhanuka Director replied that on the sterile plant the utilization roughly is 90%. And the oral plant it\u2019s about 70%. [00:08:27] Rupesh Jain from Intelsense Capital enquired that in [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Orchid Pharma Ltd Q2 FY23 Earnings Conference Call Insights #ORCHPHARMA #Q2 #FY23 #Earnings #Stocks","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[10169,1115],"class_list":["post-137018","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":143178,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":137018,"position":0},"title":"Orchid Pharma Ltd Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"March 6, 2023","format":false,"excerpt":"Key highlights from Orchid Pharma Ltd (ORCHPHARMA) Q3 FY23 Earnings Concall Q&A Highlights: [00:04:43] Himanshu Upadhyay from o3 Capital asked what changed in the DLL and Orchid merger that the merger opinion has been reversed. Manish Dhanuka MD said that the basic philosophy and intent behind the merger has not\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":127794,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":137018,"position":1},"title":"Orchid Pharma Ltd Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"February 22, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=z2DK9xz1c8k Key highlights from Orchid Pharma Ltd (ORCHPHARMA) Q3 FY22 Earnings Concall Q&A Highlights: Viraj Kacharia\u00a0 from Securities Investment asked about the DLL performance for the nine months of FY23 and comparison to previous year. Sunil Gupta CFO said that nine month EBITDA is INR10 crore and sale was INR300\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":174640,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-orchpharma-q1-2026-earnings-call-transcript\/","url_meta":{"origin":137018,"position":2},"title":"Orchid Pharma Ltd (ORCHPHARMA) Q1 2026 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Orchid Pharma Ltd (NSE: ORCHPHARMA) Q1 2026 Earnings Call dated Aug. 12, 2025 Corporate Participants: Unidentified Speaker Manish Dhanuka \u2014 Managing Director Mridul Dhanuka \u2014 Executive Director Analysts: Unidentified Participant Vishal Manchanda \u2014 Analyst Rupesh \u2014 Analyst Pranav \u2014 Analyst Viraj Parekh \u2014 Analyst Rupesh \u2014 Analyst Rahul \u2014 Analyst\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":174641,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-orchpharma-q4-2025-earnings-call-transcript\/","url_meta":{"origin":137018,"position":3},"title":"Orchid Pharma Ltd (ORCHPHARMA) Q4 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Orchid Pharma Ltd (NSE: ORCHPHARMA) Q4 2025 Earnings Call dated May. 26, 2025 Corporate Participants: Unidentified Speaker Manish Dhanuka \u2014 Managing Director Mridul Dhanuka \u2014 Whole-time Director Analysts: Unidentified Participant Vishal Manchanda \u2014 Analyst Sajal Kapoor \u2014 Analyst Viraj Parekh \u2014 Analyst Rupesh Tatiya \u2014 Analyst Rohan Shah \u2014 Analyst\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":145872,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-orchpharma-q4-fy23-earnings-concall-transcript\/","url_meta":{"origin":137018,"position":4},"title":"Orchid Pharma Ltd (ORCHPHARMA) Q4 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"May 11, 2023","format":false,"excerpt":"Orchid Pharma Ltd (NSE:ORCHPHARMA) Q4 FY23 Earnings Concall dated May. 11, 2023. Corporate Participants: Manish Dhanuka\u00a0--\u00a0Managing Director Mridul Dhanuka\u00a0--\u00a0Director Analysts: Himanshu Upadhyay\u00a0--\u00a0O3 BMS -- Analyst Rupesh Thapliyal\u00a0--\u00a0-- Analyst Nitesh Dutt\u00a0--\u00a0Burman Capital -- Analyst Sajal Kapoor\u00a0--\u00a0Individual Investor Nikhil\u00a0--\u00a0SIMPL -- Analyst Aditya Sen\u00a0--\u00a0Robocapital -- Analyst Tarang Agrawal\u00a0--\u00a0Old Bridge Capital -- Analyst Agastya\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":174642,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-orchpharma-q3-2025-earnings-call-transcript\/","url_meta":{"origin":137018,"position":5},"title":"Orchid Pharma Ltd (ORCHPHARMA) Q3 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Orchid Pharma Ltd (NSE: ORCHPHARMA) Q3 2025 Earnings Call dated Feb. 12, 2025 Corporate Participants: Mridul Dhanuka \u2014 Whole-Time Director Sunil Kumar Gupta \u2014 Chief Financial Officer Analysts: Vishal Manchanda \u2014 Senior Vice President, Institutional Research Vivek Patel \u2014 Analyst Viraj Parekh \u2014 Analyst Neeraj Bukalsaria \u2014 Analyst Rupesh Tatiya\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/137018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=137018"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/137018\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=137018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=137018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=137018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}